ADC Bio: Biotech may 'hold the key' to innovation adoption

By Flora Southey contact

- Last updated on GMT

Getty/ipopba
Getty/ipopba
CDMOs need to respond to biotech innovation at an R&D level to improve efficiency in antibody-drug conjugate manufacturing, says ADC Bio.

Antibody-drug conjugates (ADCs) – composed of an antibody linked to an active cytotoxic payload – have traditionally been used for oncology indications, to target and kill cancer cells.

While UK-headquartered ADC Bio​ said indications are now expanding to include antimicrobial and anti-inflammatory targets, industry is still “some way off”​ establishing a fully optimised manufacturing process for the ADC supply chain.  

“As a product class, it’s still in its infancy and there are a number of process improvements that can be made to the production of cytotoxics, including the linkers that bind them to antibodies,” ​said ADC Bio CEO Charlie Johnson.

To speed up these processes, innovators need to focus on development at an R&D level, with contract development and manufacturing organisations (CDMOs) “seizing” industry’s initiative to drive innovation, he added.

“In particular, biotech customers may hold the key to increased adoption – as larger pharma companies might be too risk adverse – embracing innovation that delivers more efficient systems for producing their drug candidates in clinical development.”

One CDMO for supply chain efficiency?

Employing one CDMO to handle multiple processes – for example the bioconjugation of antibodies and cytotoxics and fill/finish – can reduce production time and cost to improve supply chain efficiency, said Johnson.

CDMO Lonza​ agreed that for a pharma or biotech company developing ADCs, there are “clear advantages” ​to outsourcing to a firm that offers a variety of manufacturing services.

“The ADC market is rapidly evolving and we’re seeing an increasing variety of molecules – for example novel payloads or using site-directed conjugation technologies,” ​commercial development head of bioconjugates at Lonza Pharma & Biotech, Laurent Ducry, told us.

“At our Visp site in Switzerland, customers have access to an end-to-end solution that incorporates API [active pharmaceutical ingredient] development and manufacturing – including HPAPI [highly potent API] – as well as conjugation,” ​he added.

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers